Regarding the predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable.
Chen S, Zhou C.
Am J Clin Pathol. 2024 Nov 4;162(5):537. doi: 10.1093/ajcp/aqae141.
PMID:39436748
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A.
Am J Hematol. 2023 Jan;98(1):166-179. doi: 10.1002/ajh.26751. Epub 2022 Oct 14.
PMID:36200127
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.
Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21.
PMID:30242087
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.
Oganesyan A, Madero-Marroquin R, Patel AA.
Curr Opin Hematol. 2026 Mar 1;33(2):45-50. doi: 10.1097/MOH.0000000000000907. Epub 2025 Dec 29.
PMID:41496466
Myelodysplastic/myeloproliferative neoplasms.
Cazzola M, Malcovati L, Invernizzi R.
Hematology Am Soc Hematol Educ Program. 2011;2011:264-72. doi: 10.1182/asheducation-2011.1.264.